doi: 10.1001/jama.299.19.2266.
Cholesterol drug controversy continues
- PMID: 18492963
- DOI: 10.1001/jama.299.19.2266
Item in Clipboard
Cholesterol drug controversy continues
JAMA.
.
No abstract available
Similar articles
-
Ezetimibe combines with simvastatin to tackle cholesterol. New drugs attack "bad" cholesterol in the liver and intestine.Heart Advis. 2007 Jul;10(7):7. Heart Advis. 2007. PMID: 17695657 No abstract available.
-
Amid lingering questions, FDA reprieves LDL cholesterol-lowering medication.JAMA. 2009 Feb 25;301(8):813-5. doi: 10.1001/jama.2009.196. JAMA. 2009. PMID: 19244181 No abstract available.
-
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139.Expert Opin Drug Saf. 2006 Jul;5(4):487-8. doi: 10.1517/14740338.5.4.487. Expert Opin Drug Saf. 2006. PMID: 16774486 No abstract available.
-
Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.Int J Clin Pract. 2005 Dec;59(12):1464-71. doi: 10.1111/j.1368-5031.2005.00737.x. Int J Clin Pract. 2005. PMID: 16351680 Review.
-
Ezetimibe + simvastatin (Merck/Schering-Plough).Curr Opin Investig Drugs. 2004 Sep;5(9):984-92. Curr Opin Investig Drugs. 2004. PMID: 15503655 Review.
Cited by
-
Medication Discontinuation in the IMPROVE-IT Trial.Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. doi: 10.1161/CIRCOUTCOMES.118.005041. Circ Cardiovasc Qual Outcomes. 2019. PMID: 30630361 Free PMC article. Clinical Trial.
-
Facts and ideas from anywhere.Proc (Bayl Univ Med Cent). 2009 Apr;22(2):178-87. doi: 10.1080/08998280.2009.11928510. Proc (Bayl Univ Med Cent). 2009. PMID: 19381326 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
